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Abstract: Tumor-associated macrophages (TAMs) are the main population of myeloid cells infiltrating
solid tumors and the pivotal orchestrators of cancer-promoting inflammation. However, due to
their exceptional plasticity, macrophages can be also key effector cells and powerful activators
of adaptive anti-tumor immunity. This functional heterogeneity is emerging in human tumors,
colorectal cancer (CRC) in particular, where the dynamic co-existence of different macrophage
subtypes influences tumor development, outcome, and response to therapies. Intestinal macrophages
are in close interaction with enteric microbiota, which contributes to carcinogenesis and affects
treatment outcomes. This interplay may be particularly relevant in CRC, one of the most prevalent
and lethal cancer types in the world. Therefore, both macrophages and intestinal microbiota are
considered promising prognostic indicators and valuable targets for new therapeutic approaches.
Here, we discuss the current understanding of the molecular circuits underlying the interplay between
macrophages and microbiota in CRC development, progression, and response to both conventional
therapies and immunotherapies.
Keywords: tumor-associated macrophages (TAMs); colorectal cancer (CRC); colitis-associated cancer
(CAC); microbiota; cancer immunotherapy; tumor microenvironment (TME); prognostic biomarkers;
predictive biomarkers
1. Introduction
Beyond cancer cells, the composition of the tumor microenvironment (TME) is widely recognized
as the driving force of solid tumors, influencing their development, growth, progression, and response
to therapy. Within the TME, infiltrating immune cells are important actors that can either exert
beneficial or detrimental activities [1,2]. Indeed, while immune cells can potentially recognize and
eliminate tumor cells, they can also generate a “smoldering” inflammation, instrumental to tumor
growth and progression [3,4]. Accordingly, the characterization of “immune landscape”, namely type,
density, and location of immune cells within a tumor, is increasingly being recognized for its prognostic
and predictive value. Notably, colorectal cancer (CRC) was the first tumor type for which the
prognostic value of a T cells-based Immunoscore has been pointed out as a superior prognostic
indicator, compared to the traditional TNM system [5]. The activity of T cells is tightly regulated
by myeloid cells, which are also important sculptors of non-immune components of TME, such as
blood vessels, stromal cells, and extracellular matrix [1]. Tumor-associated macrophages (TAMs)
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are the most abundant population of myeloid cells infiltrating solid tumors. Despite macrophages
can be both powerful effectors and crucial initiators of the immune response, inside the tumors,
they generally acquire an immunosuppressive, pro-angiogenic, and pro-metastatic phenotype,
therefore acting as crucial tumor promoters [6,7]. Macrophages are widely recognized for their
exceptional plasticity, namely the ability to change their functional phenotype in response to the
dynamic changes of microenvironmental signals [8]. The M1-M2 dichotomy represents a clear and
useful simplification of macrophage ductility, in vitro. Bacterial product (LPS) and Th1 cytokine
(IFNγ) induce pro-inflammatory, cytotoxic, and antigen-presenting activities (M1-polarized activation),
whereas the Th2 (IL-4 ± IL-13) cytokines promote the expression of an alternative (M2) program of
polarized activation that supports immunomodulatory, pro-resolving, and pro-angiogenic functions [9].
Under both physiological and pathological conditions, the coexistence of multiple signals obviously
results in a much more complex phenotype [10]; therefore, in vivo, macrophage plasticity emerges as a
continuum of heterogeneous functional states, variably endowed of pro-inflammatory and effector
functions (M1-skewed) or immunosuppressive and pro-healing properties (M2-skewed) [11,12].
An additional level of complexity arises from the distinct origins of the different subsets of macrophages.
Over the last decade, fate-mapping studies in mice have demonstrated that many tissue-resident
macrophages (TRMs) are a self-maintaining population of embryonic origin, which variably coexists
with macrophages that are derived from adult circulating monocytes [13,14]. Albeit macrophage
ontogeny has been mainly studied in mice, accumulating evidence based on transcriptomic profiling by
single-cell RNA sequencing has confirmed the existence of various types of embryonic TRMs in human
tissues (e.g., head, liver, lung, and skin) and has started to dissect the spatiotemporal dynamics of early
macrophage development during human embryogenesis [15]. Although gut macrophages are thought
to be exclusively replaced by circulating monocytes, recent studies have highlighted TRM populations
of embryonic origin. Flow cytometric phenotyping and fate-mapping studies in mice have indicated
the existence of a population of early seeded tissue-resident intestinal macrophages that display little to
no turnover as the animals’ age [16,17]. Accordingly, a population of long-lived macrophages has been
observed in human patients receiving intestinal transplants [18]. Therefore, in the intestine of both
mice and humans, long-lived TRMs of embryonic origin coexist with macrophages readily replaced by
circulating monocytes, through a process known as the ‘monocyte waterfall’ [19,20].
After seeding tissues, the local microenvironmental cues sculpt the transcriptional landscape
of TRMs, which, in turn, express important trophic functions, supporting the development and
homeostatic activity of the tissues in which they are located [21]. The epigenetic signature also
constitutes a sort of “memory”, which modulates the response of TRMs to the new environmental cues.
Consequently, in inflamed tissues, bone marrow-derived macrophages are functionally distinct
from TRMs and impact differentially the outcome of multiple disorders [22,23]. This macrophage
heterogeneity is increasingly appreciated also in cancer. Although in many tumor types, the majority of
TAMs results from circulating monocytes, recent evidence indicates that in brain, lung, and pancreatic
duct cancers, a significant percentage originates from TRMs [24–27]. To what extent the developmental
origin characterizes the functional heterogeneity of TAM populations is an outstanding issue
that the advent of single-cell based approaches will likely help to figure out. So far, strategies
based on depletion, M1 repolarization, or promotion of the phagocytic activity of TAMs have
been proven to be therapeutically effective in numerous pre-clinical studies that pave the way
for their clinical development [28,29]. Although such macrophage-targeted approaches might be
beneficial per se, its combination with other therapeutics will likely improve anti-cancer efficacy.
Beyond contributing to tumorigenesis, TAMs can profoundly affect the response to anti-cancer therapies,
including chemotherapy, radiotherapy, angiogenic inhibitors, as well as immunotherapies [30–33].
Undoubtedly, the unleashing of pre-existing anti-tumor immune responses through the blockage of
the immune checkpoints—cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed
cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1)—represents the breakthrough of cancer therapy of
the last decade [34]. After the approval of ipilimumab (targeting CTLA-4) and pembrolizumab
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and nivolumab (targeting PD-1) for the treatment of metastatic melanoma, the clinical benefit
of immune checkpoint blockers (ICBs) have been quickly appreciated for a growing number of
cancer types, including non-small cell lung cancer, microsatellite instability-high (MSI-H) CRC,
gastric cancer, Hodgkin lymphoma, head and neck squamous cell, hepatocellular, renal cancer,
Merkel cell, and urothelial carcinoma [35]. Despite these broad successes in several malignancies,
ICBs are now only useful on a small fraction of cancer patients, so the challenge at the forefront is
to identify new predictors of response and understand how to overcome resistance mechanisms to
enable a personalized approach of precision medicine. So far, many patient intrinsic characteristics
(e.g., age, sex, HLA genotype, and genetic polymorphisms) and tumor intrinsic determinants
(such as tumor mutational burden and TME composition) have been found associated with ICB
sensitivity [36–38]. ICBs could be effective, providing that tumor cells express immunogenic antigens
recognized by the immune system. Hence, the extent of tumor mutational burden (TMB) correlates with
the probability of expressing newly formed antigens and ICB efficacy, as well as with higher benefits to
ICB treatments [39,40]. The presence of an abundant T cell infiltrate and the expression of an IFNγ-signature,
along with the expression of PD-1 and PD-L1, are additional favorable predictors of response to ICBs
since they represent indicators of a pre-existing anti-tumor immunity [38]. Conversely, due to their
immunosuppressive activities, myeloid cells are recognized as major brakes for ICB efficacy [41–43].
Accordingly, the combination of macrophage-targeted approaches with ICBs shows promising results
in different pre-clinical models [44,45]. The therapeutic efficacy of ICBs can be also influenced by
different environmental factors, such as the diet and the microbiome. A large body of evidence has
shown that the gut microbiome makes substantial contributions to some types of cancer, in particular
gastrointestinal cancers, through both direct effects and bystander immunomodulatory activities [46].
Here, we examine the role of macrophages in CRC development, focusing on the main molecular
determinants of their pro-tumor activity, including the gut microbiota, as well as on their prognostic
and predictive significance of the response to therapy, including ICBs.
2. Molecular Pathways Underpinning the Pro-Tumor Activity of Macrophages in CRC
CRC is the third most common cancer type and a leading cause of cancer-related deaths [47].
Although early diagnosis is usually associated with a favorable outcome, CRC is often detected at
more advanced and, therefore, more challenging stages for treatment [48,49].
CRC frequently arises in patients with inflammatory bowel disease (IBD), including both Crohn’s
disease and ulcerative colitis [50–52], and progresses with the help of macrophages that sequentially
participate in IBD and CRC development and in the subsequent formation of an inflammatory TME.
Accordingly, genetic inactivation of the signal transducer and activator of transcription 3 (Stat3) in
macrophages, leading to the inactivation of anti-inflammatory IL-10 signaling, has resulted in chronic
intestinal inflammation and onset of tumor lesions [53].
Although a strong causal association exists between IBD and the development of colitis-associated
cancer (CAC), this causality accounts for only 2% of all CRCs [54], while in many cancers, oncogenic
mutations occur in the absence of pre-existing inflammation. A small percentage of CRCs (about 5%)
can be etiologically associated with hereditary cancer syndromes, among which the most common is
familial adenomatous polyposis and hereditary nonpolyposis colorectal [55,56]. An additional 10–30%
of CRCs have a family history, indicating the existence of an inherited genetic susceptibility, while up
to 75% arise sporadically through sequentially acquired genetic and epigenetic aberrations [57].
Despite the majority of CRCs arises in the absence of an obvious inflammatory process,
neoplastic transformation is associated with the construction of an inflammatory tumor-promoting
microenvironment [4,50]. Indeed, the discovery of tumor-suppressive effects of nonsteroidal
anti-inflammatory drugs (NSAIDs) dates back to 1981 [58], and aspirin hitherto remains the most
effective chemopreventive drug [49]. Albeit the adverse cardiovascular effects limit its widespread
prophylactic use, selective targeting the PGE2/EP signaling, downstream to the enzymatic activity of
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cyclooxygenases (COX), represents a potential alternative approach with less severe adverse effects
and has recently entered in the clinical trial (NCT02540291) [49].
Independent on CRC origin, TAMs are crucial regulators of tumor-promoting inflammation.
Indeed, the blockade of the CCL2/CCR2 axis, in both a preclinical model of CAC and a genetic model of
intestinal tumorigenesis (ApcMin mice), leads to the reduction of TAMs in association with significant
inhibition of tumor multiplicity and growth [59,60].
Several studies have shed light on the molecular mechanisms whereby macrophages drive neoplastic
transformation, growth, and spread (Figure 1). Albeit intestinal epithelial cells can autonomously
produce reactive oxygen species (ROS) and reactive nitrogen species (RNS), the idea that inflammatory
cells could induce DNA damage and mutations through the production of ROS and RNS has long
been suggested [61]. Accordingly, recent in vivo studies have proven that myeloid-derived ROS
can promote both initial neoplastic transformation of epithelial cells and their subsequent malignant
progression. Indeed, in mice with increased ROS production by myeloid cells, chronic dextran sulfate
sodium (DSS)-induced inflammation is sufficient to trigger the onset of CRC lesions, and treatment
with the carcinogen azoxymethane leads to the development of invasive tumors, rather than benign
adenomas [62]. Beyond oxidative stress, myeloid cells are a crucial source of inflammatory cytokines,
which can support the survival and proliferation of neoplastic cells (e.g., IL-6, IL-1, IL-23, IL-17A) or
the activation of adaptive anti-tumor immunity (e.g., IL-12, IFNγ). The transcription factor NF-κB
is a master regulator of the expression of inflammatory cytokines, anti-apoptotic, and pro-cycling
genes, therefore representing a crucial connector between inflammation and tumorigenesis [63].
Accordingly, blockage of IKKβ-dependent NF-κB activation in intestinal epithelial cells impairs
proliferation, survival, and epithelial-mesenchymal transition (EMT) of neoplastic cells, leading to
important anti-tumor effects in both models of CAC and carcinogen-induced CRC [64,65]. The impact of
myeloid-specific NF-κB activation on CRC development is more complex since the formation of different
NF-κB dimers induces distinct macrophage activation states [66], which are associated with either
tumor promotion or resistance [67,68]. Exemplary, while in a CAC model, IKKβ-dependent activation
of NF-κB in myeloid cells promotes tumor growth through the production of IL-6, which stimulates
cancer cell proliferation and survival via STAT3 [69,70], we have observed that nuclear accumulation
of p50 NF-κB in TAMs supports tumor-promoting inflammation. In particular, while CRC lesions have
shown increased expression of M2-related (Il10, Tgfb1, Ccl17, and Ccl22) and tumor-promoting genes
(Tnf and Il23a), genetic ablation of p50 has impaired IL-23 expression and enhanced M1/Th1 immune
responses, leading to a significant reduction of tumor multiplicity and growth in models of both CAC
and genetically-induced intestinal tumorigenesis [71]. Interestingly, the importance of M1-polarized
myeloid cells to restrain CRC development emerges also in the absence of IKKα and mechanistically
requires the IKKβ-driven activation of NF-κB in intestinal epithelial cells, along with the subsequent
production of monocyte-recruiting chemokines [72].
Beyond the direct pro-tumor activity on cancer cells, PGE2 signaling in infiltrating immune and
stromal cells enhances the generation of an immunosuppressive TME [73]. Interestingly, PGE2 triggers
both p50 NF-κB accumulation in macrophages [67] and their M2-skewed polarized activation.
Similar to p50−/− mice, myeloid-specific deletion of PGE2 receptor EP4 or its pharmacological
inhibition has led to a significant reduction of genetically-induced intestinal tumorigenesis (ApcMin
mice), in association with increased frequency of M1-anti-tumor macrophages [74]. PGE2 is
crucial also for the expansion and activation of myeloid-derived suppressor cells (MDSCs) [75,76].
Inhibition of PGE2/EP2 signaling by either aspirin or the PGE2 receptor EP2 antagonist AH6809
impairs both accumulation and immunosuppressive activity of CD11b+Gr1+ MDSCs, leading to
a significant reduction of CAC development [76]. Notably, we have recently demonstrated that
tumor-derived PGE2 drives the nuclear accumulation of p50 NF-κB in CD11b+Ly6G-Ly6Chigh M-MDSC,
diverting their response to IFNγ towards NO-mediated immunosuppression and reducing TNFα
expression [77]. Consistently, the ablation of p50, as well as pharmacological inhibition of EP2 by
AH6809, has reprogrammed M-MDSC towards a NOS2low/TNFαhigh phenotype, restoring the in vivo
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anti-tumor activity of IFNγ [77]. Further, circulating M-MDSCs (CD33+CD14+HLA-DRlow/− cells) of
CRC patients express the EP2 receptor and show increased nuclear accumulation of p50 in association
with the elevated expression of the immunosuppressive NOS2 [77].
Figure 1. Mechanisms and Functions Underlying the Pro-tumor Activities of Macrophages in CRC.
TAMs are key orchestrators of tumor-promoting inflammation. [1] Macrophages-derived ROS induces
DNA damage and mutations in neighboring epithelial cells, supporting neoplastic transformation
and malignant progression. [2] Commensal bacteria and microbial products activate the expression
of inflammatory cytokines via NF-κB. IL-6, IL-1β, IL-23 promote the proliferation and survival of
neoplastic cells, as well as differentiation of pro-tumorigenic Th-17 T cells. [3] During tumor development,
nuclear p50 NF-κB accumulation in TAM drives a shift in the polarized inflammatory response from
type 1 (IL-12, iNOS, CXCL-9, CXCL-10) to type 2 (TGβ, IL-10, CCL17, CCL22). This event creates
tumor-promoting conditions by hampering the cytotoxic actions of the Th1/M1-polarized immune
response. [4] Prostaglandin E2 (PGE2) exerts a pivotal role in the generation of an immunosuppressive
TME by promoting expansion and activation of myeloid-derived suppressor cells (MDSC) and
M2-skewed macrophage polarization.
Along with the suppression of anti-tumor immunity, myeloid cells produce inflammatory cytokines
(IL-23, IL-6, IL-1) that drive the expansion and activation of pro-tumorigenic T helper 17 (Th17)
cells [78,79]. In a mouse model of colorectal tumorigenesis, the barrier defects induced by initiating
lesions lead to the translocation of commensal bacteria and microbial products that trigger myeloid
cells to release a copious amount of IL-23 [80]. In turn, the immunomodulatory properties of IL-23 have
favored CRC development by inducing a tumoral IL-17 response, associated with the inhibition of NK
cell effector functions [81] and enhanced expansion and activation of Th17 cells. Several studies indicate
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that high levels of IL-17 enhance colorectal tumorigenesis [82] by activating cancer cell proliferation
and survival [80,83]. However, despite in early-stage human CRC, elevated expression of IL-23 [84]
and IL-17A [85] is recognized as unfavorable prognostic indicators, elevated expression of IL-17A in
advanced CRC appears to be associated with improved outcome [86], suggesting that, at some point,
IL-17A may stimulate anti-tumor immunity. Similarly, a dual activity of IL-1 has been reported in
CRC. In spite of a pro-tumorigenic activity of IL-1 is recognized in different human cancer types [87],
IL-1 signaling in distinct CRC-infiltrating immune cells is associated with the expression of both pro-
and anti-tumorigenic activities [88]. In the preclinical model of CRC, specific inactivation of IL-1R
in cell types other than myeloid cells has confirmed that IL-1 signaling promotes proliferation and
survival of neoplastic cells and drives both Th17 differentiation and production of pro-tumorigenic
cytokines (IL-17 and IL-22) [88]. In contrast, IL-1 signaling in myeloid cells is anti-tumorigenic. Indeed,
lack of Il1r1 in neutrophils promotes tumor-associated dysbiosis, with a consequently heightened
infiltration of bacteria into the tumor tissue, increased production of pro-tumorigenic cytokines by
TAMs, and aggressive CRC progression [88].
3. Cross-Talk between Gut Microbiota and Macrophages in CRC Development
Beyond the cumulative pro-tumorigenic effects associated with the augmented bacterial
translocation into neoplastic tissue [80], CRC development is causally associated with gut dysbiosis [46].
Characteristic alterations of the fecal microbiota are, in fact, detected in CRC patients compared to
healthy subjects, as well as in the tumor (both adenoma and cancer) compared to the adjacent healthy
mucosa [89–91]. Moreover, the transplant of stool samples from CRC patients or healthy subjects
in germ-free or microbiota-depleted mice has demonstrated that fecal microbiota of CRC patients
selectively increases chemical-induced polyps [92]. Mechanistically, fecal microbiota transplantation
(FMT) of CRC bearers support tumor development by increasing the expression of pro-tumorigenic
cytokines (e.g., IL-17A, IL-22, and IL-23), inflammatory chemokines (e.g., CCL-1, CCL-2, CCL-3, CCL-4,
CXCL-12), and genes involved in the regulation of cell cycle, stemness, apoptosis, angiogenesis, tumor
invasiveness, and metastasis [92]. In addition to bacterial dysbiosis, characteristic alterations of both
fecal virome [93,94] and mycobiome [95] have been observed in CRC patients, suggesting that along
with bacteria, virus and fungi might be exploited as novel non-invasive markers for early CRC detection.
Therefore, the understanding of the pathogenetic mechanisms underlying the pro-tumorigenic activities
of the various microbial components could highlight new targets for therapeutic interventions.
So far, most studies have focused on the most relevant bacterial components of the microbiota
(Figure 2).
Intestinal bacteria can contribute to CRC development, progression, and response to therapy
either directly, via metabolic activation of carcinogens and mutagen products (e.g., environmental
polyamine, phenols, and alkylating agents), or indirectly through the modulation of immune cell
functions [96,97]. Overall, bacterial dysbiosis weakens the intestinal barrier, favoring bacterial
translocation, macrophages activation, and the consequent establishment of chronic pro-tumorigenic
inflammation [98]. Indeed, the use of antibiotics in both CAC and genetic models of intestinal
tumorigenesis drastically reduces intestinal inflammation and CRC development [99,100].
Int. J. Mol. Sci. 2020, 21, 6866 7 of 29
Figure 2. The Interplay of Macrophages and Microbiota in CRC Development. Intestinal microbiota
can sustain carcinogenesis through macrophage-induced bystander effects. (A) The barrier defects
associated with oncogenic transformation lead to the translocation of commensal bacteria and microbial
products that trigger myeloid cells to release tumor-supporting inflammatory cytokines (e.g., IL-6,
IL-1β, and IL-23). Additionally, these cytokines trigger the expansion and activation of pro-tumorigenic
Th17 cells. (B) Fusobacterium nucleatum promotes the initial phase of CRC development through the
production of virulence factors (e.g., FadA, Fap2, RaD) that impair colonic epithelial cell junctions,
favoring its translocation and the instauration of an inflammatory tumor-promoting microenvironment.
During CRC development, F. nucleatum supports the generation of an immunosuppressive TME by
favoring the selective intra-tumor recruitment of M2-like TAMs and MDSCs. Macrophages infected by
F. nucleatum in vitro show an increased surface expression of the immunoregulatory enzyme indoleamine
2,3-dioxygenase (IDO). (C) Streptococcus gallolyticus is enriched in colonic carcinoma, promoting the
selective accumulation of tumor-infiltrating myeloid cells. In turn, TAMs and MDSCs inhibit T cells
via Arg1 and iNOS, hence supporting the generation of an immune-suppressive microenvironment
favorable to tumor progression. S. gallolyticus, Enterococcus faecalis, and B2 phylogenetic group of
Escherichia coli infect macrophages and stimulate COX-2 expression. In addition to PGE2, COX2
generates 4-hydroxy-2-nonenal (4-HNE), a diffusible breakdown product of ω-6 polyunsaturated fatty
acids, which causes DNA damage, chromosomal instability, dedifferentiation, and reprogramming of
primary colon epithelial cells.
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Multiple lines of evidence indicate the existence of a tight relationship between enteric bacteriome,
macrophages, and tumor promotion [96]. Macrophages of mice with intestinal dysbacteriosis release
pro-tumorigenic cytokines (e.g., IL-6 and TNF) and stimulate in vivo the growth of tumor xenografts,
while promoting colon cancer cell proliferation and EMT in vitro [101]. Notably, depletion of
macrophages totally abrogates the pro-tumor effect of intestinal dysbacteriosis, indicating that bacteria
require macrophages to exert pro-tumor activities [101,102]. Moreover, macrophages can drive
alterations of the microbial profile associated with CRC promotion. Indeed, in a CAC model, Bader and
colleagues demonstrated that late macrophage depletion inhibits onset and growth of tumor lesions,
in association with reduced expression of pro-tumorigenic cytokines (e.g., IL-6, IL-13, IL-10, TGFβ,
and CCL-17) and expansion of Firmicutes, a phylum endowed of anti-tumorigenic effects [103].
The release of microbial outer membrane vesicles (OMVs) is a relevant mechanism whereby bacteria
sustain carcinogenesis, through both direct and macrophage-induced bystander effects [104]. On the
one hand, OMVs transfer genetic material to tumor cells and, on the other, the OMV engagement of
TLR2/TLR4 on epithelial cells triggers the release of exosomes, which, in turn, induces macrophages to
produce pro-tumor cytokines (e.g., IL-6 and IL-18) [105].
Enteric microbiota of CRC bearers is characterized by an overall reduction of bacterial
diversity, leading to the enrichment of selected bacterial species that engage macrophage-driven
pro-tumorigenic activities. For example, Fusobacterium nucleatum promotes the initial phase of
CRC development by producing virulence factors (e.g., FadA, Fap2, RadD) that impair colonic
epithelial cell junctions and favor its translocation. This event triggers the recruitment and activation
of inflammatory cells, building up an inflammatory microenvironment that fosters neoplastic
transformation [106]. During tumor development, F. nucleatum supports the selective recruitment of
M2-like TAMs and MDSCs, leading to the generation of an immunosuppressive TME favorable to
tumor growth and progression [107]. Mechanistically, F. nucleatum triggers TAM activation through
the engagement of TLR4 and the subsequent activation of IL-6/STAT3/c-MYC signaling, supporting
their M2-skewed polarization [108]. Macrophages infected by F. nucleatum upregulate IDO on the cell
surface, suggesting an additional mechanism whereby F. nucleatum might trigger macrophage-driven
immunosuppression [106].
Prevotella and Porphyromonadacea are bacterial genera, which undergo expansion in a murine model
of CAC and enhance the release of pro-tumorigenic cytokines (e.g., TNF-α, IL-6, IL-1β, and IL-23)
by immune cells [18]. In line, the enrichment of Prevotella and Porphyromonadacea in tumor bearers
correlates with the extent of pro-tumorigenic activity that can be transferred via FMT in germ-free
mice [99].
Enterococcus faecalis, Streptococcus gallolyticus, and B2 phylogenetic group of Escherichia coli exert
their pro-tumorigenic activity via macrophage-induced bystander effects. They infect macrophages
and stimulate the expression of COX-2 and PGE2 expression, which, in turn, favors tumor onset and
growth [109–111]. E. faecalis-infected macrophages release clastogens that, in addition to causing
DNA damage and chromosomal instability [112], favor cancer cell stemness [113,114]. For example,
4-hydroxy-2-nonenal (4-HNE) is a DNA mutagen and mitotic spindle inhibitor that is generated
from ω-6 polyunsaturated fatty acids via COX2 [102]. 4-HNE also induces the activation of the
Wnt/β-catenin pathway and the expression of multiple pluripotent transcription factors (e.g., c-Myc,
Klf4, Oct4, and Sox2) in murine primary colon epithelial cells (YAMC). Similarly, exposure of YAMC
to E. faecalis-infected macrophages enhances Wnt/β-catenin activation and expression of cancer stem
cell markers (e.g., CD44, DCLK1), indicating that the interplay between E. faecalis and macrophages is
directly involved in dedifferentiation, reprogramming, and malignant transformation of primary colon
epithelial cells [114].
In a CAC model, oral pre-treatment with S. gallolyticus exacerbates both inflammation (e.g.,
IL-6, IL-1β, IL-8, CCL2, TNFα) and tumor formation. As compared to healthy colon and adenoma,
S. gallolyticus is enriched in colonic carcinoma, where it promotes the selective recruitment of TAMs and
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MDSCs, which inhibit T cells via Arg1 and NOS2 and support the generation of an immune-suppressive
microenvironment [115].
Although most studies aimed at identifying pro-tumorigenic bacterial species have focused on
strains that enrich themselves in cancer carriers (e.g., F. nucleatum, S. gallolyticus, Bacteroides fragilis,
E. coli, E. faecalis) [116–118], CRC dysbiosis is also associated with the decrease of beneficial species
(e.g., Bifidobacteria and Lactobacilli), suggesting that selective loss of anti-tumorigenic bacteria might
be an additional mechanism contributing to tumor development. According to this hypothesis,
Zagato and colleagues have recently identified two strains of bacteria—Faecalibaculum rodentium in
mice and its human homolog Holdemanella biformis—which are under-represented in tumor bearers
and can actually counteract CRC development and progression [119]. Mechanistically, both bacteria
produce short-chain fatty acids that inhibit histone H3 deacetylation, hampering calcineurin and
NFATc3 activation and tumor cell proliferation [119].
4. The Interplay between Dietary Habits, Intestinal Microbiota, and Macrophages in CRC
Gut microbiome composition is strictly influenced by different external factors, including diet [120],
physical activity [121], and alcohol consumption [122].
Dietary fibers promote the expansion of beneficial bacteria species, such as Lactobacilli and
Bifidobacteria [123], which metabolize non-digestible carbohydrates in SCFAs (e.g., propionate,
acetate, butyrate) [124]. In turn, SCFAs exert crucial immunomodulatory and anti-carcinogenic
activities [109,123]. Butyrate can modulate the immune response of colonic macrophages through the
inhibition of histone deacetylases, with a potential contribution to the maintenance of immunological
tolerance to commensal microorganisms [125]. Exposure of mouse macrophages to butyrate
downregulates LPS-induced pro-inflammatory mediators (e.g., IL-6, IL-12, and NO), restoring intestinal
immune homeostasis [125,126]. Accordingly, butyrate administration, in vivo, can mitigate intestinal
inflammation and lesions in both IBD patients and murine models [127,128]. Moreover, the combination
of SCFAs with diet- and gut microbiota-derived indole derivatives modulates the susceptibility
to intestinal inflammation in macrophages [129]. Some fiber-containing food is also rich in
bioactive plant-derived phytochemicals, such as quercetin that is endowed of anti-inflammatory
and anti-carcinogenic effects [128]. In line, quercetin administration in ApcMin mice has lowered
polyposis in association with a reduced macrophage infiltration [130]. Alternate day fasting, in mice,
inhibits colon carcinoma cell growth, without causing a reduction of body weight, but suppressing
M2 TAM polarization through the decreased generation of extracellular adenosine and consequent
inactivation of JAK1/STAT3 signaling pathway [131]. These studies strengthen the concept that dietary
components and interventions exert crucial effects in CRC by shaping macrophage activity. In contrast
to the beneficial activity of fiber, a diet enriched in saturated fats, refined carbohydrates, and red and
processed meat, own pro-inflammatory properties and, together with obesity and low physical activity,
are recognized as key exogenous factors in CRC etiology [132].
Both the preclinical model of CRC (ApcMin mice) and clinical studies have demonstrated that
a high-fat diet (HFD) increases the incidence of CRC. Mechanistically, HFD induces dysbiosis that
supports adenoma-adenocarcinoma sequence through the CCL2/CCR2-dependent accumulation of
pro-tumoral, M2-polarized TAMs [133]. High intake of red and processed meats is also associated with
a high intake of preservatives (such as nitrates and nitrites) and carcinogenic chemicals produced during
meat processing and cooking, such as heterocyclic amines and polycyclic aromatic hydrocarbons [134].
Additionally, nutrients enriched in red meat, such as choline and carnitine, are metabolized by gut
microbiota in products (e.g., trimethylamine and trimethylamine N-Oxide) that have been associated
with an increased risk of CRC [135,136].
Overnutrition and imbalanced diets contribute to obesity, a chronic inflammatory status associated
with a significant decrease in the diversity of the gut microbiota, including a significant reduction of
beneficial Bacteroides species [137]. In addition, diet-induced obesity enhances chemically-induced
CAC in mice by heightening inflammation. In particular, high IL-6 production skews macrophage
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activation towards a tumor-promoting phenotype, which, in turn, favors CCL20-dependent immune
cell recruitment and CAC development [138].
The importance of a healthy lifestyle for CRC prevention is strengthened by the observation
that individuals with the highest level of physical activity have a lower risk of developing CRC [121].
Conversely, wrong lifestyle behaviors, such as alcohol intake, is recognized as a major risk factor for
CRC development. Beyond the carcinogenic effects of its metabolites, ethanol can directly induce intestinal
inflammation through multiple pathways [139]. Ethanol increases intestinal permeability, as well as microbial
dysbiosis, bacterial overgrowth, and alterations in the mucosal immune system [139,140]. Gut barrier
dysfunction results in increased exposure of immune cells to LPS, leading to a pro-tumorigenic
inflammatory response, exacerbated production of ROS, and cytokines, such as IL-6 and IL-18 [139,141].
In addition, chronic ethanol feeding increases AOM/DSS-induced CAC by enhancing immune cell
infiltration and inflammatory cytokines production [142].
Altogether, this evidence demonstrates an important impact of diet on microbiota composition
and activation status of macrophages, suggesting its crucial role in the pathogenesis of intestinal
inflammation and in the development of CRC [143].
5. Macrophages as Prognostic and Predictive Biomarker in Human CRC
Although the pro-tumoral activity of TAM during CRC development has been clearly demonstrated
by preclinical studies, their impact on human CRC progression is still controversial [144–147]. In contrast
to most solid cancers [32], some studies indicate total TAM infiltration is found unable to predict
outcome [148,149], suggesting that different states of activation of macrophage subsets could be decisive
in human CRC. In line, simultaneous accumulation of M1- (NOS2+) and M2-polarized (CD163+)
macrophage populations is observed in human CRC tumors [150,151]. A recent meta-analysis indicates
that pan-macrophages (CD68+) are favorably associated with overall survival [152]; however, CD68
can occasionally be expressed in stromal and cancer cells themselves; therefore, the data obtained
by using this marker should be carefully assessed. Moreover, patients’ stratification by macrophage
subtypes highlights that a high density of CD163+ (M2-skewed) macrophages is associated with a
poorer outcome [153]. In agreement, in two independent cohorts of consecutive CRC patients with
pathologic stage II, a high frequency of M2-skewed macrophages, identified as a high CD206/CD68 ratio,
is significantly associated with disease recurrence and shorter overall survival [154]. Further, the type of
TAM infiltrate changes between MSI-H and MSI-low (MSI-L) tumors [155], suggesting that stratification
by MMR status should be advisable to improve the prognostic value of TAM infiltrate [152].
An additional level of complexity is related to the spatial localization of TAM, as several
pieces of evidence suggest that TAM may exert different functions in relation to their inner or
peripheral tumor localization. In particular, TAMs located at the invasive front would exert beneficial
activities [147,156], whereas intra-tumoral macrophages appear to play tumor-promoting roles [157] or
be unable to predict outcome [152].
Combining the TAM location and functional phenotype could represent a strategy to improve
their prognostic value. According to this, in a series of 150 CRC cases, the combination of CD68
as a macrophage lineage marker, CD80 as a marker of anti-tumor (M1) macrophages, and CD163
as a marker of pro-tumor (M2) macrophages has corroborated that distinct macrophage subtypes
are differentially distributed throughout the tumor and are associated with different outcomes [158].
In line with previous studies, CD163 is observed to be expressed by almost 40% of TAMs, in particular
those that are located at tumor invasive front [158]. In contrast to NOS2-expressing TAMs [151],
the use of CD80 as a marker of M1-polarized macrophages has shown that, in comparison to adjacent
healthy mucosa, the majority of intra-tumoral macrophages downregulate CD80 and are, therefore,
skewed towards an immunosuppressive phenotype [158]. Indeed, within stage III tumors, higher
CD68 infiltration in the intra-tumoral regions is associated with decreased overall survival, and a
higher CD80/CD163 ratio at the tumor invasive front correlates with a favorable outcome [158].
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Confirming the tumor-promoting activity of M2-skewed macrophages, recognizable by nuclear
accumulation of p50 NF-κB, we have observed in a cohort of 49 CRC patients (stage II/III) that
accumulation of p50+ TAMs at the invasive margin is negatively correlated with M1 (IL12A) and Th1
(TBX21) gene expression and is associated with worse outcome [71].
In vivo evaluation of macrophage plasticity and diversity is challenging. Whereas most of the
current studies have used a single marker of polarized activation, new approaches that allow the
simultaneous analysis of multiple markers (Table 1) could improve the prognostic significance of
TAM subsets in CRC. For example, imaging mass cytometry using metal-tagged antibodies might be
pursued for multiplex protein detection, enabling the identification of TAM subpopulations within the
context of the tissue structure. Transcriptomic profiling by single-cell RNA-Seq (scRNA-Seq) analysis
is a powerful approach, able to provide a comprehensive map of the different macrophage subtypes.
Recently, the characterization of human and mouse CRC lesions by scRNA-Seq has identified distinct
myeloid populations associated with a differential sensitivity to CSF1R blockade and responsiveness
to anti-CD40 treatment [159]. TAM can also influence the effectiveness of cytoreductive therapies,
either antagonizing or synergizing the anti-tumor activity of these treatments. Therefore, depending
on the treatment, the prognostic value of TAM may change accordingly. For example, for stage II
colon cancer, a high CD206/CD68 ratio is both an unfavorable prognostic biomarker and a positive
predictive biomarker of response to postoperative adjuvant chemotherapy [154]. Similarly, within
stage III tumors, higher CD68 infiltration of the invasive front is associated with a poor outcome [158],
whereas, for patients that undergo to 5-fluorouracil (5-FU) adjuvant therapy, the extent of CD68+ TAM
infiltration is positively correlated with the overall survival [154].
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6. The Interplay of Macrophages and Microbiota in Conventional Anti-Cancer Therapies
Radiotherapy and chemotherapy remain the leading strategies for controlling tumor spread and
growth in patients with advanced and inoperable CRC lesions. Therapy regimens based on the different
combinations of 5-FU, oxaliplatin, irinotecan, and capecitabine are the backbone of CRC treatment.
Macrophages generally curtail chemotherapy efficacy by orchestrating a tumor-promoting
response and by providing a protective niche for cancer stem cells. However, TAMs can also
synergize with selected drugs, and, under certain conditions, an abundant TAM infiltrate enhances the
chemotherapy efficacy [28]. This is the case of 5-FU, a chemotherapeutic capable of reprogramming
macrophages towards an M1-anti-tumor phenotype [160]. Moreover, certain cytotoxic agents, such as
oxaliplatin, can induce “immunogenic cell death” (ICD), which stimulates the uptake and presentation of
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tumor-associated antigen by DCs to T cells [161]. Although ICD can also be induced by radiotherapy,
in irradiated mice, the monocytes recruited to the tumor generally differentiate into immunosuppressive
and tissue repairing macrophages, thus contributing to tumor relapse [162,163]. In contrast,
neoadjuvant low-dose irradiation limits this pro-tumoral differentiation of macrophages [164],
suggesting that phenotypic maturation of macrophages is dependent on radiation-absorbed dose.
Multiple lines of evidence indicate that the outcome of anti-cancer therapies is also deeply
influenced by gut microbiota [165]. Intestinal microbiota can both increase efficacy or toxicity of
chemotherapy by different mechanisms, including modulation of drug metabolism, activation of
inflammatory pathways, and host immune response [165,166]. For example, the F. nucleatum
promotes autophagy in the CRC cells, supporting chemoresistance [167]. In contrast, Clostridia spp.
produces glucoronidases that reactivate irinotecan in the distal intestine, contributing to the typical
gastrointestinal side effects [168,169]. Gut bacteria are also essential for radiation-induced enteritis,
and germ-free mice are resistant to the lethal gastrointestinal effects of radiation [170].
Microbiota exerts a shaping activity on tumor-associated myeloid cell functions [166]. In different
tumor models (e.g., CRC, melanoma, lymphoma), the efficacy of platinum-based chemotherapy is
strictly dependent on the presence of both gut microbiota and myeloid cells [171]. Platinum compounds
are genotoxic drugs that act through the formation of DNA-adducts and the production of mitochondrial
ROS by tumor-associated inflammatory cells and cancer cells themselves [171,172]. The activity
of platinum compounds is enhanced by microbiota, which increases the paracrine production of
ROS by inducing NADPH oxidase 2 (NOX2) in myeloid cells [171]. In line, either germ-free or
microbiota-depleted tumor-bearing mice show an impaired response to platinum compounds, along
with defective production of ROS by tumor-infiltrating myeloid cells [171]. Similarly, myeloid cell
depletion hampers oxaliplatin efficacy, corroborating the existence of a symbiotic relationship between
microbiota and the immune system [171].
7. The Interplay of Macrophages and Microbiota in ICBs-Based Immunotherapy
In the last decade, ICB-based immunotherapy has achieved unprecedented clinical results in many
solid tumors [173–175]. Despite initial studies of ICB in CRC had given disappointing results [176–178],
the stratification by TMB and immune infiltrate has highlighted the efficacy of PD-1 and CTLA4
neutralization in a small subgroup of CRC patients characterized by an MSI-H phenotype due to
a deficient DNA mismatch repair (dMMR) system [179–181]. In these patients, the inactivation of
one of the four MMR genes increases the mutational rate 20 times, leading in more than 80% of
cases to a high TMB [155,182]. dMMR/MSI-H tumors are also largely infiltrated by immune cells,
in particular CD8+ and T-helper 1 (Th1) CD4+ lymphocytes expressing high levels of CTLA-4 and
PD-1, whereas myeloid cells expressing the immune checkpoint ligands (PD-L1) are mainly located at
the tumor-stroma interface [183–185]. The gene signature of dMMR/MSI-H tumors includes type I
interferons, pro-inflammatory cytokines, and Th1-recruiting chemokines (e.g., CXCL9 and CXC10),
indicating that tumor intrinsic IFN-signaling is functional [186,187]. All together, these features indicate
a pre-existing anti-tumor immunity that is hampered by the immune checkpoints and can be efficiently
unleashed by ICBs. Accordingly, in 2017, the anti-PD-1 inhibitors pembrolizumab (KeytrudaVR,
Merck) and nivolumab (OpdivoVR, Bristol-Myers Squibb) have been approved by the Food and Drug
Administration (FDA) for the treatment of patients with dMMR/MSI-H CRC.
Unfortunately, dMMR/MSI-H CRC represents only a small fraction of all CRC, whereas the
majority of patients harboring a proficient MMR (pMMR)/MSI-low (MSI-L) tumor do not benefit
from ICB treatment alone [188]. Despite most of pMMR/MSI-L CRC has low TMB and is poorly
infiltrated by either T cells or inhibitory ligand-expressing cells, 2–3% of pMMR/MSI-L tumors exhibit an
ultramutated phenotype characterized by a high number of frameshift mutations [189]. This phenotype
is due to the inactivation of DNA polymerase epsilon or delta (POLE, POLD), which are involved in
DNA replication and repair [190,191]. The POLE-mutated pMMR/MSI-L tumors are also enriched
in PD1+CD8+ T cells and PD-L1+CD68+ macrophages and express high levels of pro-inflammatory
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cytokines and immune checkpoints (PD-1, PD-L1, and CTLA-4) [192,193], overall suggesting that
they can benefit ICBs [194]. In line, Jun and colleagues have recently reported the first case of
clinical response to pembrolizumab from a treatment-refractory patient, harboring a POLE-mutated
pMMR/MSI-L metastatic CRC [195,196].
Beyond the molecular features of CRC, accumulating insights indicate TAMs control ICB
responsiveness (Figure 3).
For example, using intravital imaging to follow fluorescently labeled PD-1 antibodies in CRC
bearing mice, Arlauckas et al. have observed that TAMs capture anti-PD-1 via their Fcγ receptors,
limiting its availability for tumor-infiltrating CD8+ T cells [42]. Consequently, the blockade of Fcγ
receptors increases the therapeutic efficacy of tumor-infiltrating CD8+ T cells [42]. Beyond T cells,
neutralization of PD-1/PD-L1 can also act through a direct effect on macrophages. Indeed, in both CRC
mouse models and human patients, PD-1 has been found expressed by a TAM subset characterized
by an M2-skewed profile and impaired phagocytic activity against tumor cells [197]. Accordingly,
the genetic ablation of PD-L1 increases PD-1+ TAM phagocytosis in vivo, inhibits tumor growth,
and improves the survival of CRC-bearing mice in a macrophage-dependent manner [197]. These
observations support PD-1 as a key determinant for limiting anti-tumor immunity and highlight the
therapeutic potential of enhancing TAM effector activities in CRC immunotherapy.
To date, the CD47/signal-regulatory protein α (Sirpα) is the best characterized innate immune
checkpoint, which regulates phagocytic and cytotoxic activities of myeloid cells. Sirpα is an inhibitory
receptor expressed by myeloid cells, which binds CD47, a “don’t eat me” signal physiologically
expressed by normal tissue and hematopoietic cells. Sirpα/CD47 axis blocks phagocytosis, preventing
the destruction of self-tissues; however, in the tumor context, the upregulation of CD47 by neoplastic
cells represents a mechanism to escape immune clearance [198]. Accordingly, in a wide range of
human cancers, CD47 expression levels are associated with a worse outcome, and multiple clinical
trials have started to evaluate its neutralization by monoclonal antibodies, in particular by combinatory
strategies [199,200]. Although in gastrointestinal malignancies, anti-CD47 therapies are still in the early
stages of development, the prognostic and therapeutic values of Sirpα/CD47 are being confirmed by a
growing number of studies [201]. In CRC patients, single-nucleotide polymorphisms in CD47 [202]
and high CD47 expression [203] are found to be associated with poor prognosis and distant metastasis.
Interestingly, CD47 expression correlates with both CD44 expression and EMT, suggesting CD47 as
a promoter of cancer cell stemness, tumor spreading, and resistance to PD-1/PDL-1 inhibitors [203].
In different CRC models, the expression of the inhibitory immune checkpoint receptor Sirpα in TAM
increases during tumor progression, in association with impaired phagocytosis of tumor cells [204].
Mechanistically, CRC-derived lactate induces the expression of Sirpα through the sequential activation
of the transcription factors—Ap-2α and Elk-1 [204]. This evidence fosters additional studies to evaluate
the therapeutic potential of this phagocytic checkpoint in CRC. In particular, given that synergistic
action of Sirpα/CD47 blockade and ICBs has been reported in other tumor types [200], neutralization
of Sirpα represents an attractive approach to increase the responsiveness of CRC patients to ICB.
Recently ST2, the only known receptor of IL-33, has emerged as an attractive immune checkpoint
for new combinatory strategies. In CRC patients, ST2 has been overexpressed in TAM and
associated with low CD8+ T cell cytotoxicity and poor outcome [205]. In the preclinical models
of CRC, ST2-expressing TAMs increase during tumor progression, promoting the generation of an
immunosuppressive TME favorable for CRC growth [205]. Indeed, pharmacological inhibition of
ST2+ TAMs recruitment by an IL-33 traps fusion protein, or lack of host ST2 significantly reduces CRC
growth in a macrophage-dependent manner. Genetic depletion of ST2 also increases the frequency
and functions of intratumor CD8+ T cells and acts synergistically with anti-PD-1 checkpoint blockade.
Therefore, ST2 is an additional immune checkpoint whose neutralization might be exploited to alleviate
the immunosuppressive TME and broaden the number of CRC patients who can benefit from ICB [205].
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Figure 3. Responsiveness of CRC Patients to ICB-based Immunotherapy. Multiple determinants
influence the efficacy of ICB-based immunotherapy in CRC patients (A). Overall, high TMB, high IFN
signature, a massive infiltrate of PD-L1-expressing TAMs, CD8+ and Th1 CD4+ T-cells expressing high
levels of CTLA-4 and PD-1 are recognized as crucial determinants of ICB responsiveness. Anti-PD-1
therapy is approved for dMMR/MSI-H tumors, whereas pMMR/MSI- L tumors are resistant. DNA
polymerase epsilon or delta (POLE, POLD)-mutated CRC might be responsive to ICB due to an
ultramutated phenotype associated with an elevated inflammatory cytokine gene expression and strong
immune cell infiltration, enriched in CD8+ PD-1+ T cells and PD-L1+ TAMs. (B) TAMs control ICB
responsiveness through multiple mechanisms. TAMs capture anti-PD-1 antibodies via Fcγ receptors,
limiting their availability for tumor-infiltrating CD8+ T cells. Blockade of Fcγ receptors enables CD8+
T cells activation and cytotoxic tumor cell killing, increasing the therapeutic efficacy of ICBs. TAMs
express different inhibitory receptors (e.g., PD-1 and Sirpα) that impair the uptake of tumor cells.
Neutralization of PD-1/PD-L1 or Sirpα/CD47 axes restores macrophage-dependent tumor cell clearance
and might increase ICB efficacy. The upregulation of ST2 by its ligand IL-33 supports TAM-suppressive
activities. Pharmacological inhibition of the ST2/IL-33 axis augments the frequency and functions of
intra-tumor CD8+ T cells and might act synergistically with anti–PD-1 therapy. (C) The composition
of the gut microbiota affects the responsiveness to ICBs. FMT of ICB responsive patients or oral
supplementation of selective bacteria species (Akkermansia muciniphila and Bacteroides fragilis) enhances
the efficacy of PD-1 and CTLA-4 blockade in both germ-free and dysbiosis mice.
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The diversity and composition of the gut microbiota are found to be key determinants in response
to treatment with ICB [206–208]. In different epithelial cancers, an abnormal gut microbiome due to
the use of antibiotics is associated with ICB resistance [206]. Different studies have demonstrated that
FMT of ICB responding patients in germ-free mice enhances the efficacy of anti- PD-L1 therapy,
leading to augmented T-cell responses and improved tumor control [207,208]. Metagenomics
of patient stool samples at diagnosis have identified a significant association between clinical
responses to ICB and the relative abundance of selective bacterial species (e.g., Bifidobacterium longum,
Collinsella aerofaciens, Enterococcus faecium, Akkermansia muciniphila, Bacteroides fragilis, Bacteroides
cepacia, and Bacteroides thetaiotaomicron) [206,208]. Interestingly, oral supplementation in non-responder
mice, with some of these enriched bacterial species, such as Akkermansia muciniphila and Bacteroides
fragilis, respectively, restores the efficacy of PD-1 and CTLA-4 blockade [206,209]. In CRC patients,
the influence of the microbiota on CRC responsiveness to ICBs is still largely unexplored; however, some
preclinical evidence has pointed out an association between enteric bacteria and the efficacy of
immunotherapeutic approaches based on CpG-oligodeoxynucleotide (CpG-ODN). In subcutaneous
CRC models, intra-tumoral injection of CpG-ODN along with neutralization of IL-10 have shown
impressive results in conventional mice, but are largely ineffective in microbiota-depleted mice [171].
CpG-ODN triggers TAM to release a copious amount of TNF that leads to a rapid tumor hemorrhagic
necrosis [171,210]. Of note, mice showing elevated TNF in response to CpG-ODN show a different
composition of the enteric microbiota. Specifically, the abundance of Gram- Alistipes and Gram+
Ruminococcus bacteria positively correlates with TNF production and response to CpG-ODN, whereas
the presence of commensal Lactobacillus spp is associated with resistance [171,211].
8. Conclusions and Future Perspectives
Independently on CRC origin, TAMs emerge at the crossroads of the inflammatory pathways,
driving tumor development and response to therapy. Due to their inherent functional plasticity,
macrophage can play a dual role, contributing to anti-tumor immunity or supporting the development
of an immunosuppressive TME that promotes tumor progression and resistance to therapy.
Deciphering the heterogeneity of TAMs and its relevance in the interplay with both cancer cells
and the other cell components of the TME is the challenge to better define the prognostic and
predictive value of TAMs, as well as the therapeutic potential of TAM-targeting approaches. New
technological advances, including scRNA-Seq, are likely to achieve this and to generate new specific
macrophage-centered strategies.
Although chemotherapy remains the first-line treatment of metastatic CRC, therapies targeting
TME-modulating factors, such as vascular endothelial growth factor, epidermal growth factor receptor,
and immune checkpoint inhibitors, have been shown to be effective in patients with specific subtypes of
CRC [212]. In an effort to increase the number of patients who can benefit from ICBs, there is growing
interest in developing combination strategies that include conventional therapies, multiple ICBs,
or co-stimulatory agonists. In particular, approaches targeting innate and adaptive immune responses
promise to generate more potent anti-cancer responses. Within this scenario, neutralization of
phagocytosis checkpoints, such as the Sirpα/CD47 axis, can enhance TAM effector activities and might
act synergistically in combination with ICB [200]. While anti-CD47 therapies have already shown
impressive results in hematologic malignancies, increasing evidence is confirming the prognostic and
therapeutic value of the Sirpα/CD47 axis in gastrointestinal cancers [201].
The impact of the microbiota on the outcome of cancer treatment and anti-tumor immunity [46]
arises new questions in the CRC field. Given that a specific microbial signature can influence the
prognosis of CRC patients and the host’s sensitivity to conventional and ICB-based immunotherapy,
manipulation of gut microbiota is a potential strategy for CRC treatment. FMT is an approach to
restore gut microbial homeostasis, which has been found effective for the treatment of resistant
Clostridium difficile infection [213], thus opening promises for other gastrointestinal disorders, such as
IBD and CRC.
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Further, probiotics can exert beneficial immunomodulatory and anti-cancer activities, and therefore,
they could be exploited for both CRC prevention as well as to improve clinical response and
reduce the collateral effects of anti-tumor treatments [214]. Notably, several probiotics modulate
macrophage functions, either limiting the production of inflammatory mediators (e.g., Lactobacillus
fermentum) or enhancing macrophage activation (cell surface molecules of Lactobacillus strains, bacterial
extracts of Lactobacillus rhamnosus GG and Bifidobacterium adolescentis) [215,216]. The former could
be useful in the CRC prevention setting, whereas the latter might be exploited in combination with
immunotherapy. Accordingly, preclinical studies have demonstrated that oral administration of
Alistipes shaii, in antibiotics pre-treated mice, reestablishes the production of TNF by TAMs during
anti-IL-10/CpG-ODN therapy [171]. Of note, in a preclinical model of CAC, the combined administration
of Lactobacillus acidophilus lysates with anti-CTLA-4 enhances anti-tumor immune responses, leading to
a significant reduction of CRC development. In comparison to ICB alone, the administration of the
probiotic reshapes tumor immune infiltrate by increasing tumor-infiltrating CD8 +T cells and effector
memory T cells and by reducing immunosuppressive T regulatory cells and M2 macrophages [217].
Finally, the tumor homing capacity of some bacteria can be exploited to enhance
anti-tumor immunity. For example, in an orthotopic tumor model of CRC, it has been demonstrated
that engineered attenuated Salmonella strains expressing TLR5 ligand activate an immune response,
leading to a significant anti-tumor activity [184]. The direct modulation of immune cells through the
administration of bacterial products is, therefore, an alternative strategy to engage anti-cancer immunity.
Ligands for TLRs or other innate receptors are being developed for clinical use in combination with
cancer therapies [218].
In addition to bacteria, the human microbiota contains a virome and the mycobiome. Although our
understanding of both is in its infancy, growing evidence indicates that alterations in the enteric virome
and mycobiome are associated with CRC, so a better understanding of the composition of microbial
communities may open new strategies for therapeutic modulation of the microbiota.
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